We use cookies to ensure that we give you the best website experience. By continuing to use this site, you are agreeing to our use of cookies.

Close

Media Centre

Latest News

Please browse our press releases below. These are all in PDF format. If you do not have an appropriate PDF reader, please download it from the Adobe website New window openshere.

Kyowa Kirin International announces that it is to expand its headquarters facility in Galashiels
02 February 2017
Download (309 KB)
Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency
05 January 2017
Download (639 KB)
Kyowa Hakko Kirin Announces First Patient Enrolled Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia (XLH)
26 October 2016
Download (124 KB)
Kyowa Hakko Kirin Announces Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia
20 September 2016
Download (643 KB)
Kyowa Hakko Kirin Announces Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
20 September 2016
Download (517 KB)
US Food and Drug Administration Granted Breakthrough Therapy Designation for KRN23 for Pediatric X-Linked Hypophosphatemia
28 June 2016
Download (102 KB)
Kyowa Hakko Kirin Announces Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
21 April 2016
Download (78 KB)
ProStrakan rebrands as Kyowa Kirin
18 April 2016
Download (116 KB)
ProStrakan and AstraZeneca enter into agreement for rights to Moventig® in Europe
29 February 2016
Download (237 KB)
ProStrakan completes acquisition of Archimedes
06 August 2014
Download (96 KB)
ProStrakan Agreement to Acquire Archimedes
11 July 2014
Download (82 KB)
ProStrakan Announces Board Changes
11 November 2013
Download (127 KB)
ProStrakan Announces EU Launch of Sancuso
30 September 2013
Download (76 KB)
ProStrakan Announces 3 Abstracts for Sancuso
09 July 2013
Download (155 KB)
ProStrakan Acquires Breast Cancer Product for the US
01 October 2012
Download (90 KB)
Orexo acquires US commercial rights of Abstral and ProStrakan acquires the corresponding rights in the EU and rest of the world
04 June 2012
Download (85 KB)
ProStrakan Partners with Aptalis for Rectiv in the US
09 January 2012
Download (177 KB)
FDA Approves Shared REMS for all TIRF Pain Treatments
30 December 2011
Download (37 KB)
ProStrakan Announces New Chief Executive
07 July 2011
Download (101 KB)
ProStrakan Receives FDA Approval for Rectiv for the Treatment of Moderate to Severe Pain Associated with Chronic Anal Fissures
22 June 2011
Download (220 KB)

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.